Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Roche Reports Unprecedented lidERA Phase III Results Positioning Giredestrant As A Potential New Standard Of Care For ER Positive Early Stage Breast Cancer

Author: Benzinga Newsdesk | November 18, 2025 01:41am

At interim analysis, giredestrant demonstrated a statistically significant and clinically meaningful benefit versus standard-of-care endocrine monotherapy
These unprecedented results support its potential as a new standard-of-care endocrine therapy in the early-stage setting
Data to be presented at an upcoming medical meeting and shared with health authorities around the world
lidERA is the second positive phase III readout for giredestrant following evERA presented at ESMO 20251

Posted In: RHHBF RHHBY RHHVF